<![CDATA[Genmab - DuoBody technology]]>Bispecific antibodies, also known as dual-targeting molecules bind to two different epitopes either on the same or on different targets. This may improve the antibodies' specificity and efficacy in inactivating the disease target cells. Watch this short video to learn how Genmab's DuoBody® technology platform draws inspiration from nature to enable the discovery, generation and large-scale production of effective bispecific antibodies.

Visit https://https://www.genmab.com/research-innovation/ to learn more about .

]]>https://dev.proinvestor.com/forum/topic/442565/genmab-duobody-technologyRSS for NodeTue, 07 Jul 2026 09:49:07 GMTWed, 14 Apr 2021 02:49:26 GMT60<![CDATA[Reply to Genmab - DuoBody technology on Wed, 14 Apr 2021 08:18:40 GMT]]>Pappano...Du finder først nyhederne her på Proinvestor. Vi havde en god debat om denne i Genmabchatten i går.

Just a moment...

favicon

(www.proinvestor.com)

]]>https://dev.proinvestor.com/forum/post/9466387https://dev.proinvestor.com/forum/post/9466387Wed, 14 Apr 2021 08:18:40 GMT<![CDATA[Reply to Genmab - DuoBody technology on Wed, 14 Apr 2021 07:26:26 GMT]]>"I pipelinen findes blandt andet produkter som Epcoritamab og DuoBodyPD-L1x4-1BB samt HexaBody-CD38. I et scenarie, hvor alle produkter godkendes, estimerer Jyske Bank, at kursen kan kravle op i 4200 kr., hvilket svarer til en fordobling af den nuværende kurs".

Link Preview Image
Siden kunne ikke findes | Euroinvestor

favicon

Euroinvestor (www.euroinvestor.dk)

]]>https://dev.proinvestor.com/forum/post/9466385https://dev.proinvestor.com/forum/post/9466385Wed, 14 Apr 2021 07:26:26 GMT